Skip to main content
  • Register
  • Help
  • Contact us

OncoCyte Corp (OCX) Common Stock NPV

Sell:$4.28 Buy:$4.30 Change: $0.16 (3.60%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:$4.28
Buy:$4.30
Change: $0.16 (3.60%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:$4.28
Buy:$4.30
Change: $0.16 (3.60%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment. Its initial focus will be confirmatory diagnostics, utilizing liquid biopsy technology, for use in conjunction with imaging to confirm initial diagnoses within certain oncology indications. In addition, it will be developing screening diagnostics as replacements for screening imaging procedures. For some indications, it will also be pursuing the probability of recurrence of a specific cancer through the development of prognostics or companion diagnostics that help a physician determine which therapy is the optimal treatment for the patient. It offers diagnostic tests for lung, breast and bladder cancer.

Contact details

Address:
15 CUSHING
IRVINE
92618
United States
Telephone:
+1 (949) 4097600
Website:
www.oncocyte.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
OCX
ISIN:
US68235C1071
Market cap:
$383.22 million
Shares in issue:
88.91 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Cavan Redmond
    Independent Chairman of the Board
  • Ronald Andrews
    President, Chief Executive Officer, Director
  • Mitchell Levine
    Chief Financial Officer
  • Albert Parker
    Chief Operating Officer
  • Tony Kalajian
    Senior Vice President, Chief Accounting Officer
  • Padma Sundar
    Senior Vice President - Marketing and Market Access
  • Lyndal Hesterberg
    Chief Scientific Officer
  • Douglas Ross
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.